retatrutide news today recency 3 The Thriving Black Market for a Powerful Weight Loss Drug Retatrutide Phase 3: TRIUMPH Program

Ozempic came out in 2017, and the semaglutide patent is set to expire ~2030

The applicability of thyroid c-cell tumors in rats and humans is not clear, and it cannot be established just by clinical trials or nonclinical studies

GLP-1 medications, by contrast, actively reduce cardiovascular risk

These agents are FDA-approved primarily for the management of type 2 diabetes mellitus and, for specific products (Wegovy, Saxenda, Zepbound), for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity

Some differences patients may see are: Potential for Federal Action: Although past federal attempts to mandate Medicaid coverage have stalled, the current administration heavily focuses on the effects of obesity on public health crises

Stopping medication without lifestyle support may lead to weight regain